1. Jha JC, Banal C, Chow BS, Cooper ME, Jandeleit-Dahm K. Diabetes and kidney disease: role of oxidative stress.
Antioxid Redox Signal 2016;25:657-684.
2. Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense.
World Allergy Organ J 2012;5:9-19.
3. Sayre LM, Smith MA, Perry G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease.
Curr Med Chem 2001;8:721-738.
4. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases.
J Hypertens 2000;18:655-673.
5. Giacco F, Brownlee M. Oxidative stress and diabetic complications.
Circ Res 2010;107:1058-1070.
6. Andreadis AA, Hazen SL, Comhair SA, Erzurum SC. Oxidative and nitrosative events in asthma.
Free Radic Biol Med 2003;35:213-225.
7. Kao MP, Ang DS, Pall A, Struthers AD. Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options.
J Hum Hypertens 2010;24:1-8.
8. Gupta A, Sharma S, Nain CK, Sharma BK, Ganguly NK. Reactive oxygen species-mediated tissue injury in experimental ascending pyelonephritis.
Kidney Int 1996;49:26-33.
9. Gupta R, Verma I, Sharma S, Ganguly NK. Prevention of tissue injury in an ascending mouse model of chronic pyelonephritis: role of free radical scavengers.
Comp Immunol Microbiol Infect Dis 2004;27:225-234.
10. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome.
Nephrol Dial Transplant 2003;18:1272-1280.
11. Tucker PS, Dalbo VJ, Han T, Kingsley MI. Clinical and research markers of oxidative stress in chronic kidney disease.
Biomarkers 2013;18:103-115.
12. Duni A, Liakopoulos V, Roumeliotis S, Peschos D, Dounousi E. Oxidative stress in the pathogenesis and evolution of chronic kidney disease: untangling Ariadne's thread.
Int J Mol Sci 2019;20:3711.
13. Dounousi E, Papavasiliou E, Makedou A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD.
Am J Kidney Dis 2006;48:752-760.
14. Hamer RA, El Nahas AM. The burden of chronic kidney disease.
BMJ 2006;332:563-564.
15. Chapter 1: Definition and classification of CKD.
Kidney Int Suppl (2011) 2013;3:19-62.
16. Tanner RM, Brown TM, Muntner P. Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease.
Curr Hypertens Rep 2012;14:152-159.
17. Granata S, Zaza G, Simone S, et al. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease.
BMC Genomics 2009;10:388.
18. Choi BH, Kang KS, Kwak MK. Effect of redox modulating NRF2 activators on chronic kidney disease.
Molecules 2014;19:12727-12759.
19. Holterman CE, Read NC, Kennedy CR. Nox and renal disease.
Clin Sci (Lond) 2015;128:465-481.
20. Gorin Y, Block K. Nox4 and diabetic nephropathy: with a friend like this, who needs enemies?
Free Radic Biol Med 2013;61:130-142.
21. Fortuño A, Beloqui O, San José G, Moreno MU, Zalba G, Díez J. Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidase-dependent superoxide production in patients with early chronic kidney disease.
Kidney Int Suppl 2005;61(99):S71-S75.
22. DuPont JJ, Ramick MG, Farquhar WB, Townsend RR, Edwards DG. NADPH oxidase-derived reactive oxygen species contribute to impaired cutaneous microvascular function in chronic kidney disease.
Am J Physiol Renal Physiol 2014;306:F1499-F1506.
23. Gondouin B, Jourde-Chiche N, Sallee M, et al. Plasma xanthine oxidase activity is predictive of cardiovascular disease in patients with chronic kidney disease, independently of uric acid levels.
Nephron 2015;131:167-174.
24. Terawaki H, Murase T, Nakajima A, et al. The relationship between xanthine oxidoreductase and xanthine oxidase activities in plasma and kidney dysfunction.
J Clin Exp Nephrol 2017;2:31.
25. Wever R, Boer P, Hijmering M, et al. Nitric oxide production is reduced in patients with chronic renal failure.
Arterioscler Thromb Vasc Biol 1999;19:1168-1172.
26. Baylis C. Nitric oxide deficiency in chronic kidney disease.
Am J Physiol Renal Physiol 2008;294:F1-F9.
27. Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with chronic renal disease.
Kidney Int 2000;58:1261-1266.
28. Williams S, Malatesta K, Norris K. Vitamin D and chronic kidney disease. Ethn Dis 2009;19(4 Suppl 5):S5-11.
29. Noronha IL, Fujihara CK, Zatz R. The inflammatory component in progressive renal disease: are interventions possible?
Nephrol Dial Transplant 2002;17:363-368.
30. Li N, Karin M. Is NF-kappaB the sensor of oxidative stress?
FASEB J 1999;13:1137-1143.
31. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1.
EMBO J 1991;10:2247-2258.
32. Simmons EM, Langone A, Sezer MT, et al. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients.
Transplantation 2005;79:914-919.
33. Cachofeiro V, Goicochea M, de Vinuesa SG, Oubiña P, Lahera V, Luño J. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease.
Kidney Int Suppl 2008;(111):S4-S9.
34. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency.
Kidney Int 2003;63:179-185.
35. Suvakov S, Damjanovic T, Stefanovic A, et al. Glutathione S-transferase A1, M1, P1 and T1 null or low-activity genotypes are associated with enhanced oxidative damage among haemodialysis patients.
Nephrol Dial Transplant 2013;28:202-212.
36. Karamouzis I, Sarafidis PA, Karamouzis M, et al. Increase in oxidative stress but not in antioxidant capacity with advancing stages of chronic kidney disease.
Am J Nephrol 2008;28:397-404.
37. Yu M, Kim YJ, Kang DH. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress.
Clin J Am Soc Nephrol 2011;6:30-39.
38. Gouroju S, Rao PV, Bitla AR, Vinapamula KS, Manohar SM, Vishnubhotla S. Role of gut-derived uremic toxins on oxidative stress and inflammation in patients with chronic kidney disease.
Indian J Nephrol 2017;27:359-364.
39. Liu WC, Tomino Y, Lu KC. Impacts of indoxyl sulfate and p-cresol sulfate on chronic kidney disease and mitigating effects of AST-120.
Toxins (Basel) 2018;10:367.
40. Gao H, Liu S. Role of uremic toxin indoxyl sulfate in the progression of cardiovascular disease.
Life Sci 2017;185:23-29.
41. Fahal IH. Uraemic sarcopenia: aetiology and implications.
Nephrol Dial Transplant 2014;29:1655-1665.
42. Liu WC, Wu CC, Lim PS, et al. Effect of uremic toxin-indoxyl sulfate on the skeletal system.
Clin Chim Acta 2018;484:197-206.
43. Gryp T, Vanholder R, Vaneechoutte M, Glorieux G. p-Cresyl sulfate.
Toxins (Basel) 2017;9:52.
44. Liakopoulos V, Roumeliotis S, Zarogiannis S, Eleftheriadis T, Mertens PR. Oxidative stress in hemodialysis: causative mechanisms, clinical implications, and possible therapeutic interventions.
Semin Dial 2019;32:58-71.
45. Cristol JP, Canaud B, Rabesandratana H, Gaillard I, Serre A, Mion C. Enhancement of reactive oxygen species production and cell surface markers expression due to haemodialysis.
Nephrol Dial Transplant 1994;9:389-394.
46. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure.
Free Radic Biol Med 1996;21:845-853.
47. Canaud B, Cristol J, Morena M, Leray-Moragues H, Bosc J, Vaussenat F. Imbalance of oxidants and antioxidants in haemodialysis patients.
Blood Purif 1999;17:99-106.
48. Morena M, Delbosc S, Dupuy AM, Canaud B, Cristol JP. Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysis-associated inflammation.
Hemodial Int 2005;9:37-46.
49. Koenig JS, Fischer M, Bulant E, Tiran B, Elmadfa I, Druml W. Antioxidant status in patients on chronic hemodialysis therapy: impact of parenteral selenium supplementation.
Wien Klin Wochenschr 1997;109:13-19.
50. Kalantar-Zadeh K, Brennan ML, Hazen SL. Serum myeloperoxidase and mortality in maintenance hemodialysis patients.
Am J Kidney Dis 2006;48:59-68.
51. Maher ER, Wickens DG, Griffin JF, Kyle P, Curtis JR, Dormandy TL. Increased free-radical activity during haemodialysis?
Nephrol Dial Transplant 1987;2:169-171.
52. Masakane I. Review: clinical usefulness of ultrapure dialysate. Recent evidence and perspectives.
Ther Apher Dial 2006;10:348-354.
53. Lonnemann G. Chronic inflammation in hemodialysis: the role of contaminated dialysate.
Blood Purif 2000;18:214-223.
54. Jun M, Venkataraman V, Razavian M, et al. Antioxidants for chronic kidney disease.
Cochrane Database Syst Rev 2012;10:CD008176.
55. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
Am J Kidney Dis 2006;47:51-59.
56. Yelken B, Caliskan Y, Gorgulu N, et al. Reduction of uric acid levels with allopurinol treatment improves endothelial function in patients with chronic kidney disease.
Clin Nephrol 2012;77:275-282.
57. Filiopoulos V, Hadjiyannakos D, Vlassopoulos D. Febuxostat renoprotection in CKD patients with asymptomatic hyperuricemia.
Am J Kidney Dis 2016;67:989-990.
58. Liao CY, Chung CH, Wu CC, et al. Protective effect of N-acetylcysteine on progression to end-stage renal disease: necessity for prospective clinical trial.
Eur J Intern Med 2017;44:67-73.
59. Sahin G, Yalcin AU, Akcar N. Effect of N-acetylcysteine on endothelial dysfunction in dialysis patients.
Blood Purif 2007;25:309-315.
60. Gill PS, Wilcox CS. NADPH oxidases in the kidney.
Antioxid Redox Signal 2006;8:1597-1607.
61. Jha JC, Gray SP, Barit D, et al. Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy.
J Am Soc Nephrol 2014;25:1237-1254.
62. Gorin Y, Cavaglieri RC, Khazim K, et al. Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes.
Am J Physiol Renal Physiol 2015;308:F1276-F1287.
63. Cha JJ, Min HS, Kim KT, et al. APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db/db mice from renal injury.
Lab Invest 2017;97:419-431.
64. Kwon G, Uddin MJ, Lee G, et al. A novel pan-Nox inhibitor, APX-115, protects kidney injury in streptozotocin-induced diabetic mice: possible role of peroxisomal and mitochondrial biogenesis.
Oncotarget 2017;8:74217-74232.
65. Ito M, Tanaka T, Nangaku M. Nuclear factor erythroid 2-related factor 2 as a treatment target of kidney diseases.
Curr Opin Nephrol Hypertens 2020;29:128-135.
66. Nezu M, Suzuki N, Yamamoto M. Targeting the KEAP1-NRF2 system to prevent kidney disease progression.
Am J Nephrol 2017;45:473-483.
67. Chin MP, Bakris GL, Block GA, et al. Bardoxolone methyl improves kidney function in patients with chronic kidney disease stage 4 and type 2 diabetes: post-hoc analyses from bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes study.
Am J Nephrol 2018;47:40-47.
68. Bhogade RB, Suryakar AN, Joshi NG, Patil RY. Effect of vitamin E supplementation on oxidative stress in hemodialysis patients.
Indian J Clin Biochem 2008;23:233-237.
69. Deicher R, Hörl WH. Vitamin C in chronic kidney disease and hemodialysis patients.
Kidney Blood Press Res 2003;26:100-106.
70. Giannikouris I. The effect of N-acetylcysteine on oxidative serum biomarkers of hemodialysis patients.
Hippokratia 2015;19:131-135.
71. Princen HM, van Duyvenvoorde W, Buytenhek R, et al. Supplementation with low doses of vitamin E protects LDL from lipid peroxidation in men and women.
Arterioscler Thromb Vasc Biol 1995;15:325-333.
72. Wratten ML, Navino C, Tetta C, Verzetti G. Haemolipodialysis.
Blood Purif 1999;17:127-133.
73. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial.
Lancet 2000;356:1213-1218.
74. Boudouris G, Verginadis II, Simos YV, et al. Oxidative stress in patients treated with continuous ambulatory peritoneal dialysis (CAPD) and the significant role of vitamin C and E supplementation.
Int Urol Nephrol 2013;45:1137-1144.
75. Kim MJ, Frankel AH, Donaldson M, et al. Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition.
Kidney Int 2011;80:851-860.
76. Aytaç MB, Deveci M, Bek K, Kayabey Ö, Ekinci Z. Effect of cholecalciferol on local arterial stiffness and endothelial dysfunction in children with chronic kidney disease.
Pediatr Nephrol 2016;31:267-277.
77. Seibert E, Heine GH, Ulrich C, Seiler S, Köhler H, Girndt M. Influence of cholecalciferol supplementation in hemodialysis patients on monocyte subsets: a randomized, double-blind, placebo-controlled clinical trial.
Nephron Clin Pract 2013;123:209-219.
78. Meireles MS, Kamimura MA, Dalboni MA, Giffoni de Carvalho JT, Aoike DT, Cuppari L. Effect of cholecalciferol on vitamin D-regulatory proteins in monocytes and on inflammatory markers in dialysis patients: a randomized controlled trial.
Clin Nutr 2016;35:1251-1258.
79. Alvarez JA, Law J, Coakley KE, et al. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial.
Am J Clin Nutr 2012;96:672-679.
80. Sepidarkish M, Farsi F, Akbari-Fakhrabadi M, et al. The effect of vitamin D supplementation on oxidative stress parameters: a systematic review and meta-analysis of clinical trials.
Pharmacol Res 2019;139:141-152.
81. Norris KC, Olabisi O, Barnett ME, et al. The role of vitamin D and oxidative stress in chronic kidney disease.
Int J Environ Res Public Health 2018;15:2701.
82. Zhang F, Liu H, Liu D, et al. Effects of RAAS inhibitors in patients with kidney disease.
Curr Hypertens Rep 2017;19:72.
83. Renke M, Lizakowski S, Tylicki L, et al. Aliskiren attenuates oxidative stress and improves tubular status in non-diabetic patients with chronic kidney disease: placebo controlled, randomized, cross-over study.
Adv Med Sci 2014;59:256-260.
84. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.
Ann Intern Med 2001;135:73-87.
85. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease.
Ann Intern Med 2008;148:30-48.
86. Chung EY, Ruospo M, Natale P, et al. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Cochrane Database Syst Rev 2020;10:CD007004.
87. Hollenberg NK. Direct renin inhibition and the kidney.
Nat Rev Nephrol 2010;6:49-55.
88. Niki E. Interaction of ascorbate and alpha-tocopherol.
Ann N Y Acad Sci 1987;498:186-199.
89. Busch M, Göbert A, Franke S, et al. Vitamin B6 metabolism in chronic kidney disease: relation to transsulfuration, advanced glycation and cardiovascular disease.
Nephron Clin Pract 2010;114:c38-c46.
90. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD.
J Am Soc Nephrol 2008;19:1613-1619.
91. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.
Clin J Am Soc Nephrol 2010;5:1388-1393.
92. Schramm L, La M, Heidbreder E, et al. L-arginine deficiency and supplementation in experimental acute renal failure and in human kidney transplantation.
Kidney Int 2002;61:1423-1432.
93. Fatouros IG, Douroudos I, Panagoutsos S, et al. Effects of L-carnitine on oxidative stress responses in patients with renal disease.
Med Sci Sports Exerc 2010;42:1809-1818.
94. Matera M, Bellinghieri G, Costantino G, Santoro D, Calvani M, Savica V. History of L-carnitine: implications for renal disease.
J Ren Nutr 2003;13:2-14.
95. Yeung CK, Billings FT 4th, Claessens AJ, et al. Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress.
BMC Nephrol 2015;16:183.
96. Mehmetoglu I, Yerlikaya FH, Kurban S, Erdem SS, Tonbul Z. Oxidative stress markers in hemodialysis and peritoneal dialysis patients, including coenzyme Q10 and ischemia-modified albumin.
Int J Artif Organs 2012;35:226-232.
97. Mas E, Barden A, Burke V, et al. A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease.
Clin Nutr 2016;35:331-336.
98. Khajehdehi P, Pakfetrat M, Javidnia K, et al. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study.
Scand J Urol Nephrol 2011;45:365-370.
99. Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation.
Curr Atheroscler Rep 2004;6:461-467.
100. Saldanha JF, Leal Vde O, Stenvinkel P, Carraro-Eduardo JC, Mafra D. Resveratrol: why is it a promising therapy for chronic kidney disease patients?
Oxid Med Cell Longev 2013;2013:963217.